Skip to main content

20.08.2018 | Trauma | Ausgabe 12/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2018

Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study

Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 12/2018
Abdussalam M. Abdullatif, Tamer A. Macky, Mona M. Abdullatif, Khaled Nassar, Salvatore Grisanti, Hassan A. Mortada, Mahmoud M. Soliman



To determine the short-term safety of human recombinant decorin protein in preventing proliferative vitreoretinopathy (PVR) in perforating injuries.


This is a prospective, single-center, open-label, interventional case series. Single intravitreal injection of decorin 200 μg (n = 4) or 400 μg (n = 8) was given 48 h after injury. At the tenth day, pars plana vitrectomy was done whenever indicated. Flash electroretinogram (ERG) was done before and 3 months post-injection. We assessed ocular inflammation, ERG changes, and retinal layer integrity by optical coherence tomography (OCT). Systemic and vitreous pharmacokinetics were also evaluated.


Twelve patients (12 eyes) with perforating globe injuries (zone III) were included and followed for a median of 6 months. Intravitreal decorin injection was well tolerated with no ocular or systemic safety adverse events. Decorin retinal safety was demonstrated anatomically by intact retinal layer by OCT, and functionally by flash ERG which did not show any significant worsening during the study and the final mean logMAR best-corrected visual acuity (BCVA) which was 1.15 (20/280) and 0.7 (20/100) for groups A and B, respectively, and ≥ 20/200 in 75% of all eyes. Decorin serum and vitreous levels were elevated following trauma, with higher and extended levels following intravitreal injection.


No short-term safety concerns were detected after a single intravitreal injection of decorin in patients with perforating injuries.

Trial registration

ClinicalTrials.​gov ID: NCT02865031

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Über diesen Artikel

Weitere Artikel der Ausgabe 12/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde